In this article
sirolimus-protein-bound-particles-is-approved-for-malignant-perivascular-epithelioid-cell-tumor
Jan 2022: For adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumours, the Food and Drug Administration licenced sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro, Aadi Bioscience, Inc.) (PEComa).
Efficacy was tested in 31 patients with locally advanced unresectable or metastatic malignant PEComa in AMPECT (NCT02494570), a multicenter, single-arm clinical study. On days 1 and 8 of each 21-day cycle, patients received 100 mg/m2 sirolimus protein-bound particles until disease progression or intolerable toxicity.
AMPECT Trial Efficacy, Safety, and Dosage
Overall response rate (ORR) and duration of response (DOR) were the key efficacy outcome measures, as determined by a blinded independent central review using RECIST v.1.1. The ORR was 39 percent (95 percent CI: 22 percent, 58 percent), with two patients responding completely. The median DOR was not met (95 percent CI: 6.5 months, not estimable). 67 percent of respondents had a response that lasted more than 12 months, and 58 percent had a response that lasted more than 24 months.
Stomatitis, weariness, rash, infection, nausea, edoema, diarrhoea, musculoskeletal discomfort, decreased weight, decreased appetite, cough, vomiting, and dysgeusia were the most prevalent side events (30 percent). Decreased lymphocytes, increased glucose, decreased potassium, decreased phosphate, decreased haemoglobin, and elevated lipase were the most prevalent grade 3 to 4 laboratory abnormalities (6%).
Until disease progression or intolerable toxicity, the recommended dosage is 100 mg/m2 given as an IV infusion over 30 minutes on days 1 and 8 of each 21-day cycle.
Click this link for full prescribing information for Fyarro.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.